Clinical Trial Update: Pharmacodynamic Study of Emixustat Hydrochloride in Subjects With Macular Atrophy Secondary to Stargardt Disease [Phase 2]

View source ↗

Summary

Phase 2 pharmacodynamic study of emixustat hydrochloride in Stargardt disease–related macular atrophy completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Macular Atrophy
• Stargardt Disease

Drugs mentioned

• Emixustat hydrochloride (emixustat hydrochloride)

Snippet

Sponsor: Kubota Vision Inc. | Conditions: Stargardt Disease, Macular Atrophy | Phase 2 | Status: COMPLETED | Results posted: 2021-04-27